No Data
No Data
Oral vaccines have broad prospects. O'Brien, Homer, gives Vaxart (vaxart.US) an 'outperform' rating against the large cap market.
Initiating coverage on Vaxart (VXRT.US) with an outperform rating and target price of $4, which is expected to outperform the overall market.
Oppenheimer Starts Vaxart at Outperform, Cites Oral Vaccine Focus
HilleVax, Inc.: Prudent Cost Management Amidst Trial Setbacks – Hold Rating Justified
Express News | HC Wainwright & Co. Reiterates Neutral on HilleVax, Maintains $2 Price Target
HilleVax Analyst Ratings
HilleVax, Inc: Hold Rating Amid Vaccine Efficacy Concerns and Financial Uncertainty
No Data
Ziggz420 : $ARCA biopharma (ABIO.US)$ still in it
silverelf Ziggz420 : Same![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)